A Study to Evaluate MAR002 for Acromegaly

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Marea Therapeutics
Study ID
NCT07641179
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acromegaly

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • MAR002 — DRUG
    Subcutaneous injection
  • Placebo — DRUG
    Subcutaneous injection

Study Details

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly

Key Dates

First listed
Jun 11, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Aug 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
72 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MAR002 Dose 1
    Subcutaneous injection
  • Experimental: MAR002 Dose 2
    Subcutaneous injection
  • Experimental: MAR002 Dose 3
    Subcutaneous injection
  • Placebo Comparator: Matched Placebo
    Subcutaneous Placebo

Primary Outcome Measure

Number of participants with TEAEs (treatment-emergent adverse events), SAEs (serious adverse events), and other laboratory endpoints [ Time Frame: Baseline to Week 16 ]

Locations (3)

FacilityCityStateZIPSite coordinators
St. Joseph's Hospital and Medical CenterPhoenixArizona85013
Mary Thornton
[email protected]
6024062768
Kevin Yuen (PRINCIPAL_INVESTIGATOR)
Endocrinology Associates, IncColumbusOhio43201
Camila Caudy
[email protected]
6143546215
Elena Christofides (PRINCIPAL_INVESTIGATOR)
Consano Clinical ResearchSan AntonioTexas78258
Marissa Flores
[email protected]
2105454900
Daniel Katselnik (PRINCIPAL_INVESTIGATOR)

Find similar trials in Phoenix, AZ

By research site
St. Joseph's Hospital and Medical Center· Phoenix, AZEndocrinology Associates, Inc· Columbus, OHConsano Clinical Research· San Antonio, TX

Related Studies